The Global hydrocephalus market is expected to reach USD 2,592,720.77 thousand by 2031 from USD 1,587,759.20 thousand in 2023, growing with a CAGR of 6.5% in the forecast period of 2024 to 2031.
Market Segmentation
Global Hydrocephalus Market, By Type (Congenital Hydrocephalus, Acquired Hydrocephalus, Normal-Pressure Hydrocephalus, and Ex-Vacuo Hydrocephalus), Diagnostic & Treatment (Diagnosis and Treatment), End Users (Hospitals, Clinics, Diagnostic Centers, and Academic Institutions and Research Organizations), Country (U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Russia, Netherlands, Switzerland, Belgium, Turkey, Ireland, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, Saudi Arabia, South Africa, U.A.E., Israel, Egypt, and Rest of Middle East and Africa) - Industry Trends and Forecast to 2031.
Overview of Global Hydrocephalus Market Dynamics
- Driver
- Increasing incidence of neurological conditions
- Restraint
- Poor reimbursement policies
- Opportunity
- Growing support by healthcare organizations and government bodies
Market Players
Some of the key market players operating in the global hydrocephalus market are:
- Aesculap, Inc. - a B. Braun company
- Integra LifeSciences
- G.SURGIWEAR LTD
- MOLLER Medical GmbH
- Anuncia Inc.
- CHRISTOPH MIETHKE GMBH & CO. KG
- KARL STORZ SE & Co. KG
- Proteses, inc.
- Medtronic
- natus
- Desu Medical
- Bicakcilar
- Spiegelberg GmbH & Co.KG
- Sophysa
- KANEKA MEDIX CORP
TABLE OF CONTENTS
1 INTRODUCTION 32
- 1.1 OBJECTIVES OF THE STUDY 32
- 1.2 MARKET DEFINITION 32
- 1.3 OVERVIEW OF GLOBAL HYDROCEPHALUS MARKET 32
- 1.4 LIMITATIONS 33
- 1.5 MARKETS COVERED 33
2 MARKET SEGMENTATION 36
- 2.1 MARKETS COVERED 36
- 2.2 GEOGRAPHICAL SCOPE 37
- 2.3 YEARS CONSIDERED FOR THE STUDY 38
- 2.4 CURRENCY AND PRICING 38
- 2.5 DBMR TRIPOD DATA VALIDATION MODEL 39
- 2.6 MULTIVARIATE MODELLING 42
- 2.7 TYPE LIFELINE CURVE 42
- 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 43
- 2.9 DBMR MARKET POSITION GRID 44
- 2.10 VENDOR SHARE ANALYSIS 45
- 2.11 SECONDARY SOURCES 46
- 2.12 ASSUMPTIONS 46
3 EXECUTIVE SUMMARY 47
4 PREMIUM INSIGHTS 49
5 GLOBAL HYDROCEPHALUS MARKET: REGULATIONS 52
- 5.1 REGULATIONS IN U.S. 52
- 5.2 REGULATIONS IN EUROPE 52
- 5.3 REGULATIONS IN INDIA 52
- 5.4 REGULATIONS IN JAPAN 53
- 5.5 REGULATIONS IN BRAZIL 53
6 MARKET OVERVIEW 54
- 6.1 DRIVERS 56
- 6.1.1 INCREASING INCIDENCE OF NEUROLOGICAL CONDITIONS 56
- 6.1.2 GROWING NUMBER OF NEW-BORNS AFFECTED BY HYDROCEPHALUS 56
- 6.1.3 INCREASING ADAPTATION OF ADVANCED PROGRAMMABLE VALVES 57
- 6.1.4 RISING AWARENESS ABOUT HYDROCEPHALUS 57
- 6.2 RESTRAINTS 58
- 6.2.1 POOR REIMBURSEMENT POLICIES 58
- 6.2.2 DELETERIOUS COMPLICATIONS WITH HYDROCEPHALUS DEVICES 58
- 6.3 OPPORTUNITIES 59
- 6.3.1 GROWING SUPPORT BY HEALTHCARE ORGANIZATIONS AND GOVERNMENT BODIES 59
- 6.3.2 GROWING HEALTHCARE EXPENDITURE 60
- 6.3.3 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYERS 60
- 6.4 CHALLENGES 61
- 6.4.1 HIGH PRODUCT RECALL SCENARIO 61
- 6.4.2 LACK OF ACCESSIBILITY OF HYDROCEPHALUS PRODUCTS 61
7 GLOBAL HYDROCEPHALUS MARKET, BY TYPE 62
- 7.1 OVERVIEW 63
- 7.2 CONGENITAL HYDROCEPHALUS 66
- 7.3 ACQUIRED HYDROCEPHALUS 66
- 7.4 NORMAL-PRESSURE HYDROCEPHALUS 67
- 7.5 EX-VACUO HYDROCEPHALUS 67
8 GLOBAL HYDROCEPHALUS MARKET, BY DIAGNOSTICS & TREATMENT 68
- 8.1 OVERVIEW 69
- 8.2 DIAGNOSTICS 72
- 8.2.1 MAGNETIC RESONANCE IMAGING (MRI) 72
- 8.2.2 CT SCAN - HEAD 72
- 8.2.3 HEAD ULTRASOUND 73
- 8.3 TREATMENT 73
- 8.3.1 SURGERY - SHUNT INSERTION, BY PRODUCT TYPE 74
- 8.3.1.1 HYDROCEPHALUS VALVES 74
- 8.3.1.2 HYDROCEPHALUS CATHETERS 74
- 8.3.1.2.1 ADJUSTABLE PRESSURE VALVES 74
- 8.3.1.2.2 FIX PRESSURE VALVES 75
- 8.3.2 SURGERY - SHUNT INSERTION, BY AGE GROUP 75
- 8.3.2.1 PEDIATRIC 75
- 8.3.2.2 ADULT 75
- 8.3.3 VENTRICULOSTOMY 75
- 8.3.4 MEDICATION 75
- 8.3.5 TREATMENT, BY AGE GROUP 76
- 8.3.6 INFANTS 76
- 8.3.7 CHILDREN 76
- 8.3.8 ADULTS 76
9 GLOBAL HYDROCEPHALUS MARKET, BY END USERS 77
- 9.1 OVERVIEW 78
- 9.2 HOSPITALS 81
- 9.3 CLINICS 81
- 9.4 DIAGNOSTIC CENTERS 82
- 9.5 ACADEMIC INSTITUTIONS AND RESEARCH ORGANIZATIONS 82
- 9.5.1 HOSPITALS 83
- 9.5.2 AMBULATORY AND SURGICAL CENTERS 83
- 9.5.3 HOSPITALS 83
- 9.5.4 CLINICS 83
- 9.5.5 DIAGNOSTIC CENTER 84
- 9.5.6 SURGICAL CENTERS 84
- 9.5.7 AMBULATORY SURGICAL CENTERS 84
- 9.5.8 OTHERS 84
10 GLOBAL HYDROCEPHALUS MARKET, BY REGION 85
- 10.1 OVERVIEW 86
- 10.2 NORTH AMERICA 89
- 10.2.1 U.S. 93
- 10.2.2 CANADA 97
- 10.2.3 MEXICO 101
- 10.3 EUROPE 105
- 10.3.1 GERMANY 110
- 10.3.2 FRANCE 114
- 10.3.3 U.K. 118
- 10.3.4 ITALY 122
- 10.3.5 SPAIN 126
- 10.3.6 RUSSIA 130
- 10.3.7 TURKEY 134
- 10.3.8 IRELAND 138
- 10.3.9 BELGIUM 142
- 10.3.10 NETHERLANDS 146
- 10.3.11 SWITZERLAND 150
- 10.3.12 REST OF EUROPE 154
- 10.4 ASIA-PACIFIC 155
- 10.4.1 JAPAN 160
- 10.4.2 CHINA 164
- 10.4.3 SOUTH KOREA 168
- 10.4.4 INDIA 172
- 10.4.5 AUSTRALIA 176
- 10.4.6 SINGAPORE 180
- 10.4.7 THAILAND 184
- 10.4.8 MALAYSIA 188
- 10.4.9 INDONESIA 192
- 10.4.10 PHILIPPINES 196
- 10.4.11 VIETNAM 200
- 10.4.12 REST OF ASIA-PACIFIC 204
- 10.5 SOUTH AMERICA 205
- 10.5.1 BRAZIL 209
- 10.5.2 ARGENTINA 213
- 10.5.3 REST OF SOUTH AMERICA 217
- 10.6 MIDDLE EAST AND AFRICA 218
- 10.6.1 SOUTH AFRICA 222
- 10.6.2 SAUDI ARABIA 225
- 10.6.3 U.A.E. 228
- 10.6.4 EGYPT 231
- 10.6.5 ISRAEL 234
- 10.6.6 REST OF MIDDLE EAST & AFRICA 237
11 GLOBAL HYDROCEPHALUS MARKET, COMPANY LANDSCAPE 238
- 11.1 COMPANY SHARE ANALYSIS: GLOBAL 238
- 11.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 239
- 11.3 COMPANY SHARE ANALYSIS: EUROPE 240
- 11.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 241
12 SWOT ANALYSIS 242
13 COMPANY PROFILE 243
- 13.1 MEDTRONIC 243
- 13.1.1 COMPANY SNAPSHOT 243
- 13.1.2 REVENUE ANALYSIS 243
- 13.1.3 COMPANY SHARE ANALYSIS 244
- 13.1.4 PRODUCT PORTFOLIO 244
- 13.1.5 RECENT DEVELOPMENTS 244
- 13.2 AESCULAP, INC. - A B. BRAUN COMPANY 245
- 13.2.1 COMPANY SNAPSHOT 245
- 13.2.2 COMPANY SHARE ANALYSIS 245
- 13.2.3 PRODUCT PORTFOLIO 246
- 13.2.4 RECENT DEVELOPMENT 246
- 13.3 INTEGRA LIFESCIENCES 247
- 13.3.1 COMPANY SNAPSHOT 247
- 13.3.2 REVENUE ANALYSIS 247
- 13.3.3 COMPANY SHARE ANALYSIS 248
- 13.3.4 PRODUCT PORTFOLIO 248
- 13.3.5 RECENT DEVELOPMENT 249
- 13.4 SPIEGELBERG GMBH & CO. KG 250
- 13.4.1 COMPANY SNAPSHOT 250
- 13.4.2 COMPANY SHARE ANALYSIS 250
- 13.4.3 PRODUCT PORTFOLIO 251
- 13.4.4 RECENT DEVELOPMENT 251
- 13.5 BICAKCILAR 252
- 13.5.1 COMPANY SNAPSHOT 252
- 13.5.2 COMPANY SHARE ANALYSIS 252
- 13.5.3 PRODUCT PORTFOLIO 253
- 13.5.4 RECENT DEVELOPMENTS 253
- 13.6 ANUNCIA INC 254
- 13.6.1 COMPANY SNAPSHOT 254
- 13.6.2 PRODUCT PORTFOLIO 254
- 13.6.3 RECENT DEVELOPMENT 254
- 13.7 CHRISTOPH MIETHKE GMBH & CO. KG 255
- 13.7.1 COMPANY SNAPSHOT 255
- 13.7.2 PRODUCT PORTFOLIO 255
- 13.7.3 RECENT DEVELOPMENT 256
- 13.8 DESU MEDICAL 257
- 13.8.1 COMPANY SNAPSHOT 257
- 13.8.2 PRODUCT PORTFOLIO 257
- 13.8.3 RECENT DEVELOPMENT 257
- 13.9 G.SURGIWEAR LTD 258
- 13.9.1 COMPANY SNAPSHOT 258
- 13.9.2 PRODUCT PORTFOLIO 258
- 13.9.3 RECENT DEVELOPMENT 258
- 13.10 HPBIO 259
- 13.10.1 COMPANY SNAPSHOT 259
- 13.10.2 PRODUCT PORTFOLIO 259
- 13.10.3 RECENT DEVELOPMENT 259
- 13.11 KANEKA MEDIX CORP 260
- 13.11.1 COMPANY SNAPSHOT 260
- 13.11.2 REVENUE ANALYSIS 260
- 13.11.3 PRODUCT PORTFOLIO 262
- 13.11.4 RECENT DEVELOPMENTS 262
- 13.12 KARL STORZ SE & CO. KG 263
- 13.12.1 COMPANY SNAPSHOT 263
- 13.12.2 PRODUCT PORTFOLIO 263
- 13.12.3 RECENT DEVELOPMENT 263
- 13.13 MOLLER MEDICAL GMBH 264
- 13.13.1 COMPANY SNAPSHOT 264
- 13.13.2 PRODUCT PORTFOLIO 264
- 13.13.3 RECENT DEVELOPMENT 264
- 13.14 NATUS MEDICAL INCORPORATED 265
- 13.14.1 COMPANY SNAPSHOT 265
- 13.14.2 PRODUCT PORTFOLIO 265
- 13.14.3 RECENT DEVELOPMENTS 266
- 13.15 SOPHYSA 267
- 13.15.1 COMPANY SNAPSHOT 267
- 13.15.2 PRODUCT PORTFOLIO 267
- 13.15.3 RECENT DEVELOPMENTS 268
14 QUESTIONNAIRE 269
15 RELATED REPORTS 272